Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI

NMIBC-SI assesses patients' self-reported symptom burden and can be used to evaluate NMIBC treatments from the perspective of patients. The NMIBC-SI is acceptable to patients and has evidence for reliability and validity. Future validation work with patients with greater symptom burden is warranted.

Authors

Institutions

Publication Details

Journal
Journal of Patient-Reported Outcomes
Published
2025-03-27
DOI
https://doi.org/10.1186/s41687-025-00864-7
Citations
1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
2.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI

Madeleine King, David P. Smith, Jörg Henseler, Euan Green et al.
1 citations
Journal of Patient-Reported Outcomes
Bladder and Urothelial Cancer Treatments
2.01
article

Development and psychometric evaluation of a patient-reported symptom index for patients with non-muscle invasive bladder cancer: the NMIBC-SI

Madeleine King, David P. Smith, Jörg Henseler, Euan Green, Margaret-Ann Tait, Dickon Hayne, Roger Watson, Peter C. Black, Andrew Mitterdorfer, Daniel Costa, Badrinath R. Konety, Noel W. Clarke, Mark Frydenberg, Venu Chalasani, Claudia Rutherford, Stephen A. Boorjian, Nicholas Buchan, Joseph Ischia, Shomik Sengupta, Paul Anderson, Manish I. Patel, Peter Gilling, Jeffrey M. Holzbeierlein
article en
1 citations

Abstract

NMIBC-SI assesses patients' self-reported symptom burden and can be used to evaluate NMIBC treatments from the perspective of patients. The NMIBC-SI is acceptable to patients and has evidence for reliability and validity. Future validation work with patients with greater symptom burden is warranted.

Journal of Patient-Reported OutcomesVol. 9(1)
The University of Sydney (AU), University of Minnesota (US), The Royal Melbourne Hospital (AU), University of British Columbia (CA), University of Kansas (US), The University of Melbourne (AU), The University of Western Australia (AU), Royal North Shore Hospital (AU), Concord Repatriation General Hospital (AU), Monash Medical Centre (AU), Westmead Hospital (AU), Canterbury Health Laboratories (NZ), Tauranga Hospital (NZ), Eastern Health (AU), Salford Royal Hospital (GB), Northern Sydney Local Health District (AU), Mayo Clinic in Arizona (US), Christchurch Clinical Studies Trust (NZ), Australian and New Zealand Urogenital and Prostate Cancer Trials Group (AU), Canterbury District Health Board (NZ), Rata Foundation (NZ), Austin Health (AU), Monash University (AU), Universidade Nova de Lisboa (PT), University of Twente (NL), Cancer Council NSW (AU)
Cancer Australia, Fiona Stanley Hospital, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Council NSW
Reduced inequalities
Openalex Percentile: Top 18%
Bladder and Urothelial Cancer Treatments
2.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.